185 related articles for article (PubMed ID: 8806696)
21. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
[TBL] [Abstract][Full Text] [Related]
22. Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas.
Biernat W; Debiec-Rychter M; Liberski PP
Pol J Pathol; 1998; 49(4):267-71. PubMed ID: 10323080
[TBL] [Abstract][Full Text] [Related]
23. Differential alterations of the genes in the CDKN2A-CCND1-CDK4-RB1 pathway are associated with the development of head and neck squamous cell carcinoma in Indian patients.
Tripathi Bhar A; Banerjee S; Chunder N; Roy A; Sengupta A; Roy B; Roychowdhury S; Panda CK
J Cancer Res Clin Oncol; 2003 Nov; 129(11):642-50. PubMed ID: 14586645
[TBL] [Abstract][Full Text] [Related]
24. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16.
Lukas J; Parry D; Aagaard L; Mann DJ; Bartkova J; Strauss M; Peters G; Bartek J
Nature; 1995 Jun; 375(6531):503-6. PubMed ID: 7777060
[TBL] [Abstract][Full Text] [Related]
25. Lack of germline CDK6 mutations in familial melanoma.
Shennan MG; Badin AC; Walsh S; Summers A; From L; McKenzie M; Goldstein AM; Tucker MA; Hogg D; Lassam N
Oncogene; 2000 Mar; 19(14):1849-52. PubMed ID: 10777219
[TBL] [Abstract][Full Text] [Related]
26. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.
Tsuzuki T; Tsunoda S; Sakaki T; Konishi N; Hiasa Y; Nakamura M
Cancer; 1996 Jul; 78(2):287-93. PubMed ID: 8674005
[TBL] [Abstract][Full Text] [Related]
27. Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas.
Büschges R; Weber RG; Actor B; Lichter P; Collins VP; Reifenberger G
Brain Pathol; 1999 Jul; 9(3):435-42; discussion 432-3. PubMed ID: 10416984
[TBL] [Abstract][Full Text] [Related]
28. Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene.
Tsao H; Benoit E; Sober AJ; Thiele C; Haluska FG
Cancer Res; 1998 Jan; 58(1):109-13. PubMed ID: 9426066
[TBL] [Abstract][Full Text] [Related]
29. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities.
Ichimura K; Bolin MB; Goike HM; Schmidt EE; Moshref A; Collins VP
Cancer Res; 2000 Jan; 60(2):417-24. PubMed ID: 10667596
[TBL] [Abstract][Full Text] [Related]
30. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices.
Ono Y; Tamiya T; Ichikawa T; Kunishio K; Matsumoto K; Furuta T; Ohmoto T; Ueki K; Louis DN
J Neuropathol Exp Neurol; 1996 Oct; 55(10):1026-31. PubMed ID: 8857999
[TBL] [Abstract][Full Text] [Related]
31. Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines.
Shapiro GI; Park JE; Edwards CD; Mao L; Merlo A; Sidransky D; Ewen ME; Rollins BJ
Cancer Res; 1995 Dec; 55(24):6200-9. PubMed ID: 8521414
[TBL] [Abstract][Full Text] [Related]
32. Activation of the E2F transcription factor by cyclin D1 is blocked by p16INK4, the product of the putative tumor suppressor gene MTS1.
Schulze A; Zerfass K; Spitkovsky D; Henglein B; Jansen-Dürr P
Oncogene; 1994 Dec; 9(12):3475-82. PubMed ID: 7970707
[TBL] [Abstract][Full Text] [Related]
33. CDK4 is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer.
Wikman H; Nymark P; Väyrynen A; Jarmalaite S; Kallioniemi A; Salmenkivi K; Vainio-Siukola K; Husgafvel-Pursiainen K; Knuutila S; Wolf M; Anttila S
Genes Chromosomes Cancer; 2005 Feb; 42(2):193-9. PubMed ID: 15543620
[TBL] [Abstract][Full Text] [Related]
34. Infrequent methylation of CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2/p15) in primary astrocytic tumours.
Schmidt EE; Ichimura K; Messerle KR; Goike HM; Collins VP
Br J Cancer; 1997; 75(1):2-8. PubMed ID: 9000591
[TBL] [Abstract][Full Text] [Related]
35. Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma.
Yao J; Pollock RE; Lang A; Tan M; Pisters PW; Goodrich D; El-Naggar A; Yu D
Clin Cancer Res; 1998 Apr; 4(4):1065-70. PubMed ID: 9563903
[TBL] [Abstract][Full Text] [Related]
36. Clinicoprognostic significance of pRb1 pathway alterations in uterine endometrial adenocarcinoma.
Semczuk A; Cybulski M; Tomaszewski J; Rechberger T; Jakowicki JA
Cancer Genet Cytogenet; 2004 Oct; 154(2):186-9. PubMed ID: 15474160
[TBL] [Abstract][Full Text] [Related]
37. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers.
Nobori T; Miura K; Wu DJ; Lois A; Takabayashi K; Carson DA
Nature; 1994 Apr; 368(6473):753-6. PubMed ID: 8152487
[TBL] [Abstract][Full Text] [Related]
38. Lack of germ-line mutations of CDK4, p16(INK4A), and p15(INK4B) in families with glioma.
Gao L; Liu L; van Meyel D; Cairncross G; Forsyth P; Kimmel D; Jenkins RB; Lassam NJ; Hogg D
Clin Cancer Res; 1997 Jun; 3(6):977-81. PubMed ID: 9815774
[TBL] [Abstract][Full Text] [Related]
39. Mutual requirement of CDK4 and Myc in malignant transformation: evidence for cyclin D1/CDK4 and p16INK4A as upstream regulators of Myc.
Haas K; Staller P; Geisen C; Bartek J; Eilers M; Möröy T
Oncogene; 1997 Jul; 15(2):179-92. PubMed ID: 9244353
[TBL] [Abstract][Full Text] [Related]
40. Infrequent alterations of the p16INK4A gene in liver cancer.
Kita R; Nishida N; Fukuda Y; Azechi H; Matsuoka Y; Komeda T; Sando T; Nakao K; Ishizaki K
Int J Cancer; 1996 Jul; 67(2):176-80. PubMed ID: 8760583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
